Modified Coversin Polypeptides Targeting Leukotriene B4
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases mediated by leukotriene B4 and hydroxyeicosanoids lack specific targeting mechanisms, with existing drugs either inhibiting broader eicosanoid pathways or not addressing the specific effects of LTB4 and its receptors effectively.
Innovation Solution
Modified Coversin polypeptides with reduced or absent C5 binding activity are developed, retaining leukotriene/hydroxyeicosanoid binding activity, allowing them to specifically target and cage LTB4 and hydroxyeicosanoids, preventing interaction with BLT1 and BLT2 receptors and ameliorating proinflammatory effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Coversin polypeptide is used to inhibit complement pathways, then complement activation is blocked, but leukotriene binding activity is also lost
Solution Approach 1:
The Coversin polypeptide is divided into functional domains: the N-terminal region (amino acids 1-120) is modified to reduce complement binding while the C-terminal region (amino acids 120-168) is preserved to maintain leukotriene binding activity. This segmentation allows independent optimization of each functional region.
Solution Approach 2:
The complement binding function is effectively extracted or removed from the Coversin polypeptide through site-directed mutagenesis of specific residues (K36Q, K89Q, K102Q, R105Q, R108Q, R111Q), while the leukotriene binding function is preserved. This selective removal allows the protein to retain only the desired therapeutic activity.
2Adaptability or versatility
If broad eicosanoid pathway inhibition is used, then multiple eicosanoid effects are reduced, but specific LTB4 targeting is not achieved
Solution Approach 1:
The modified Coversin polypeptide exhibits local quality differentiation: it has high affinity and specificity for LTB4 (KD < 1 nM) while showing reduced activity toward other eicosanoids. This selective binding profile is achieved through specific amino acid modifications that preserve the LTB4 binding pocket while reducing broader eicosanoid interactions.
Solution Approach 2:
The binding parameters of the Coversin polypeptide are changed through site-directed mutagenesis. The dissociation constant for LTB4 binding is maintained at high affinity (KD < 1 nM), while complement binding affinity is reduced through charge reversal mutations. This parameter optimization achieves selective LTB4 targeting without broad pathway inhibition.
3Object-generated harmful factors
If existing drug treatments are used, then general inflammation is reduced, but specific neutrophil chemotaxis inhibition is not achieved
Solution Approach 1:
The modified Coversin polypeptide acts as an intermediary that specifically binds to LTB4, preventing its interaction with BLT1 and BLT2 receptors on neutrophils. This intermediary function directly blocks neutrophil chemotaxis and activation without requiring broad anti-inflammatory mechanisms, providing targeted therapy for neutrophil-mediated inflammation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified Coversin polypeptides effectively bind to leukotrienes and hydroxyeicosanoids, reducing their inflammatory impact by blocking receptor interaction, providing a targeted therapeutic approach for conditions like asthma without interfering with complement activity.
Implementation Method 1
The modified Coversin polypeptides effectively bind to leukotrienes and hydroxyeicosanoids, reducing their inflammatory impact by blocking receptor interaction
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
The invention is directed to modified Coversin polypeptides which exhibit leukotriene or hydroxyeicosanoid binding activity and reduced or absent C5 binding relative to the unmodified Coversin polypeptide; to nucleic acid molecules encoding said modified Coversin polypeptides; vectors and host cells comprising said nucleic acid molecules; and methods of treating or preventing diseases or conditions mediated by a leukotriene or hydroxyeicosanoid in a subject comprising administering said modified polypeptides or nucleic acids to a subject.